Roche Announces Results of REGN-COV 2066 Study for

Ronapreve for the Treatment in Patients Hospitalized with COVID-19

TOKYO, September 30, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Roche issued a press release today regarding results of REGN-COV 2066 study for the anti-SARS-CoV-2 monoclonal antibody Ronapreve™ [generic name: casirivimab (genetical recombination)/imdevimab (genetical recombination)] for the treatment in adult patients hospitalized with COVID-19.

Please refer to the link below for details of the press release:

Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19https://www.roche.com/media/releases/med-cor-2021-09-30.htm

Trademarks used or mentioned in this release are protected by laws.

###

Attachments

  • Original document
  • Permalink

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 30 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 September 2021 06:11:14 UTC.